Pharmaceutical Combination Comprising Epidermal Growth Factor and Secretagogue Peptide GHRP6 for the Restoration of Brain Damage

The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central...

Full description

Saved in:
Bibliographic Details
Main Authors BESADA PÉREZ, Vladimir Armando, VAZQUEZ CASTILLO, Mariela, GONZALEZ BLANCO, Sonia, PÉREZ SAAD, Héctor Manuel, ZALDIVAR VAILLANT, Tatiana, GUILLÉN NIETO, Gerardo Enrique, DIAZ REYES, Pablo Arsenio, GARCIA DEL BARCO HERRERA, Diana, HERNÁNDEZ BERNAL, Francisco, BALADRON CASTRILLO, ldania Caridad, BERLANGA ACOSTA, Jorge Amador
Format Patent
LanguageEnglish
Published 01.07.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The efficacy of the pharmaceutical combination has a broad therapeutic window: it is independent of whether the pharmacological intervention occurs in the first or further hours after the brain damage, which broadens the therapeutic window.
Bibliography:Application Number: US201917269788